1. Scrip
  2. >>Business
  3. >>Strategy

Immunovant Swaps Out Lead Assets

 
• By Jessica Merrill

The Roivant-owned company plans to initiate a broad clinical trial program for IMVT-1402 in multiple indications, prioritizing it over batoclimab, which remains in Phase III development. 

switching directions
Immunovant is switching its lead asset • Source: Shutterstock (Stockimo/Shutterstock)

Roivant Sciences Ltd.’s Immunovant Inc. is bullish about the best-in-class potential of the neonatal fragment crystallizable receptor (FcRn) inhibitor IMVT-1402, leading the company to prioritize the earlier-stage asset ahead of its late-stage FcRn program for batoclimab, which is in Phase III for myasthenia gravis (MG) and thyroid eye disease (TED).

Key Takeaways
  • Roivant’s Immunovant is prioritizing the next-generation FcRn inhibitor IMVT-1402 over batoclimab, which is in Phase III.
  • The decision follows encouraging Phase I data on IMVT-1402, supporting...

The company announced the pivot on 29 May after market close, one day ahead of Roivant’s fourth quarter sales and earnings release. Immunovant is a publicly traded company under Roivant’s...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.

More from Business

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.

Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting

 
• By Jessica Merrill

CEO Matt Gline talked to Scrip in an interview about dealmaking and the road back to commercialization.